Stay updated on NVG-111 in ROR1+ Malignancies Clinical Trial

Sign up to get notified when there's something new on the NVG-111 in ROR1+ Malignancies Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the NVG-111 in ROR1+ Malignancies Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:49:08.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update or modification in the clinical trial details of the drug NVG-111, which is a bispecific antibody drug being studied for patients with relapsed/refractory ROR1+ malignancies, including certain types of cancer such as chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).
    Difference
    0.1%
    Check dated 2024-06-06T14:49:59.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as age, health conditions, and prior treatments. Previously, this section indicated that no information was provided.
    Difference
    19%
    Check dated 2024-05-22T21:35:33.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:35:33.000Z thumbnail image

Stay in the know with updates to NVG-111 in ROR1+ Malignancies Clinical Trial

Enter your email address, and we'll notify you when there's something new on the NVG-111 in ROR1+ Malignancies Clinical Trial page.